- The report contains detailed information about Soligenix, Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Soligenix, Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
- The Soligenix, Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
- In the part that describes Soligenix, Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Soligenix, Inc. business.
About Soligenix, Inc.
Soligenix, Inc., a late-stage research and development biopharmaceutical company, focuses on developing products to treat the life-threatening side effects of cancer treatment and serious gastrointestinal diseases, as well as developing biodefense vaccines and therapeutics.
The company maintains two active business segments: BioTherapeutics and BioDefense.
The BioTherapeutics business segment intends to develop orBec (oral beclomethasone dipropionate, or oral BDP) and other biotherapeutic products, including LPM Leuprolide.
The BioDefense business segment intends to convert its ricin toxin vaccine and radiation injury program from early stage development to advanced development and manufacturing.
orBec and oral BDP: orBec represents a therapy tailored to treat the gastrointestinal manifestation of gastrointestinal Graft-versus-Host disease (GI GVHD). orBec is intended to reduce the need for systemic immunosuppressive drugs to treat acute GI GVHD. It has entered into a collaboration agreement with Numoda Corporation (Numoda) for the execution of its confirmatory Phase 3 clinical trial of orBec. The company is enrolling patients in a randomized, double blind, placebo-controlled, Phase 2 clinical trial of orBec for the prevention of acute GVHD after allogeneic hematopoietic cell transplantation (HCT) with myeloablative conditioning regimens. It has granted a license to Sigma-Tau Pharmaceuticals, Inc. to commercialize orBec in the U.S., Canada, and Mexico.
SGX201- Time Release Formulation of oral BDP: The company has initiated a Phase 1/2 clinical trial in acute radiation enteritis for which it has received fast track designation. SGX201 contains BDP, a highly potent, topically active corticosteroid that has a local effect on inflamed tissue.
LPM Leuprolide: The companys Lipid Polymer Micelle (LPM) oral drug delivery system is a proprietary platform technology designed to allow for the oral administration of peptide drugs that are water-soluble but permeable through the gastrointestinal tract. Leuprolide is a synthetic peptide agonist of gonadotropin releasing hormone, which is used in the treatment of prostate cancer in men and endometriosis in women.
RiVax: RiVax is the companys proprietary vaccine developed to protect against exposure to ricin toxin. Ricin is a recombinant derivative of the ricin A chain and a potent glycoprotein toxin, derived from the beans of castor plants. The company has initiated a program to evaluate the efficacy of RiVax in non-human primates.
SGX202 Oral BDP for GI Radiation Injury: The company intends to conduct pre-clinical studies of oral beclomethasone dipropionate (oral BDP, also the active ingredient in orBec) for the treatment of GI radiation injury.
The company faces competition in the area of biodefense vaccines from various public and private companies, universities, and governmental agencies, such as the U.S. Army.
Soligenix, Inc., formerly known as DOR BioPharma, Inc., was founded in 1987.
The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.
1. SOLIGENIX, INC. COMPANY PROFILE
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History
2. SOLIGENIX, INC. BUSINESS OVERVIEW
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units
3. SOLIGENIX, INC. SWOT ANALYSIS
4. SOLIGENIX, INC. FINANCIAL ANALYSIS
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot
5. SOLIGENIX, INC. COMPETITORS AND INDUSTRY ANALYSIS
5.1. Soligenix, Inc. Direct Competitors
5.2. Comparison of Soligenix, Inc. and Direct Competitors Financial Ratios
5.3. Comparison of Soligenix, Inc. and Direct Competitors Stock Charts
5.4. Soligenix, Inc. Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
5.4.2. Soligenix, Inc. Industry Position Analysis
6. SOLIGENIX, INC. NEWS & EVENTS
6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events
7. SOLIGENIX, INC. EXPERTS REVIEW1
7.1. Experts Opinion
7.2. Experts Estimates
8. SOLIGENIX, INC. ENHANCED SWOT ANALYSIS2
9. UNITED STATES PESTEL ANALYSIS2
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors
10. SOLIGENIX, INC. IFE, EFE, IE MATRICES2
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix
11. SOLIGENIX, INC. PORTER FIVE FORCES ANALYSIS2
12. SOLIGENIX, INC. VRIO ANALYSIS2
APPENDIX: RATIO DEFINITIONS
LIST OF TABLES
Soligenix, Inc. Key Facts
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Soligenix, Inc. Key Executives
Key Executives Biographies1
Key Executives Compensations1
Soligenix, Inc. Major Shareholders
Soligenix, Inc. History
Soligenix, Inc. Products
Revenues by Segment
Revenues by Region
Soligenix, Inc. Offices and Representations
Soligenix, Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Soligenix, Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Soligenix, Inc. Capital Market Snapshot
Soligenix, Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Soligenix, Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Soligenix, Inc. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Revenue Estimates Trend1
Earnings Estimates Trend1
LIST OF FIGURES
Soligenix, Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Soligenix, Inc. 1-year Stock Charts
Soligenix, Inc. 5-year Stock Charts
Soligenix, Inc. vs. Main Indexes 1-year Stock Chart
Soligenix, Inc. vs. Direct Competitors 1-year Stock Charts
Soligenix, Inc. Article Density Chart
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.
Enhanced SWOT Analysis
- How to use the strengths to take advantage of the opportunities?
- How to use the strengths to reduce likelihood and impact of the threats?
- How to overcome the weaknesses that obstruct taking advantage of the opportunities?
- How to overcome the weaknesses that can make the threats a reality?
Key Factors Examined by PESTEL Analysis:
- Legal – What laws and legislation will exert influence on the style the business is carried out?
IFE, EFE, IE Matrices
Porter Five Forces Analysis
- What composes a threat of substitute products and services?
- Is there a threat of new competitors entering the market?
- What is the intensity of competitive rivalry?
- How big is the bargaining power of buyers?
- How significant is the bargaining power of suppliers?
- Tangible resources
- Intangible resources
- Innovation and Creativity
- Organizational capabilities
- Costly to imitate?
- Organized properly?